|
시장보고서
상품코드
2089710
건선 치료제 시장 규모, 점유율 및 동향 분석 보고서 : 약제 클래스별, 치료법별, 투여 경로별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)Psoriasis Drugs Market Size, Share & Trends Analysis Report By Class, By Treatment, By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
건선 치료제 시장 개요
세계의 건선 치료제 시장 규모는 2025년에 232억 7,000만 달러로 평가되며, 2026년 257억 달러에서 2033년까지 548억 8,000만 달러로 확대하며, 2026-2033년 CAGR은 11.4%에 달할 것으로 예측됩니다.
2025년 기준으로 북미의 건선 치료제 시장은 전 세계 시장의 38.3%를 차지하며 가장 큰 점유율을 기록했습니다. 건선 치료제 시장은 면역조절제의 발전, 생물제제 요법의 도입 확대, 그리고 선진국 의료 시장에서 제공되는 유리한 보험 급여 지원에 힘입어 강력한 성장세를 보이고 있습니다.
출처: Grand View Research, IR 자료, 1차 인터뷰, 유료 데이터베이스
지속적인 연구개발 활동은 특히 중등도에서 중증의 건선 사례에 대한 치료법의 혁신에 기여하고 있으며, 이를 통해 표적 치료법에 대한 수요를 지원하고 있습니다. 주요 시장 동향 중 하나는 바이오시밀러로 인한 경쟁 심화이며, 이는 기존 생물제제의 경쟁 구도를 재편하는 동시에 치료 접근성을 개선하고 있습니다. 의료 종사자와 보험사 사이에서 바이오시밀러에 대한 수용도가 높아지고 있는 것은 특히 비용에 민감한 시장에서 치료비 절감과 환자의 접근성 확대에 기여하고 있습니다. 또한 기존의 전신 요법과 비교했을 때 효능 향상, 치료 효과의 지속 기간 연장, 양호한 임상 결과를 기대할 수 있으므로 시장은 첨단 인터류킨 억제제 및 표적 경구 요법으로 계속해서 전환되고 있습니다. 또한 표적 생물제제나 차세대 경구 요법에 대한 선호도가 높아지고 있는 것을 배경으로, 시장에서는 정밀 의학에 기반한 건선 관리로 크게 전환되는 추세가 나타나고 있습니다. IL-17 및 IL-23 경로를 표적으로 하는 인터류킨 억제제는 높은 피부 증상 소실률, 신속한 작용 발현, 지속적인 치료 반응을 바탕으로 계속해서 큰 상업적 성공을 거두고 있습니다. 각 제약사는 경쟁이 치열한 면역학 분야에서 제품의 입지를 강화하기 위해, 제품 수명 주기 관리 전략, 적응증 확대, 그리고 개량 제형 개발에 적극적으로 주력하고 있습니다. 또한 장기적인 질환 관리 및 동반 질환 완화에 대한 의사의 인식이 높아지고 있는 점도 첨단 건선 치료제의 사용 확대에 기여하고 있습니다.
만성 염증성 피부 질환의 유병률 증가와 장기적인 질환 관리 요법에 대한 수요 증가가 건선 치료제 시장의 성장을 지속적으로 지원하고 있습니다. 이 시장은 기존 치료법과 비교하여 효능 향상, 증상 관리 개선, 그리고 환자 예후 개선을 초래하는 첨단 생물제제 및 표적 치료제의 채택 확대에 힘입고 있습니다. 또한 의료비 증가, 전문 피부과 진료에 대한 접근성 확대, 그리고 조기 진단 및 치료에 대한 의식의 향상가 시장 확대에 더욱 기여하고 있습니다. 지속적인 제품 혁신, 바이오시밀러의 접근성 확대, 그리고 신규 건선 치료제에 대한 규제 당국의 지속적인 지원에 힘입어, 예측 기간 중 경쟁적 발전이 유지되며 시장에 유리한 성장 기회가 창출될 것으로 예상됩니다.
자주 묻는 질문
목차
제1장 조사 방법과 범위
제2장 개요
제3장 건선 치료제 시장 : 변수, 동향, 범위
제4장 건선 치료제 시장 : 약제 클래스별 사업 분석
제5장 건선 치료제 시장 : 치료별 비즈니스 분석
제6장 건선 치료제 시장 : 투여 경로별 비즈니스 분석
제7장 건선 치료제 시장 : 유통 채널별 비즈니스 분석
제8장 건선 치료제 시장 : 지역별 추정·동향 분석
제9장 경쟁 구도
KSA 26.07.20Psoriasis Drugs Market Summary
The global psoriasis drugs market size was valued at USD 23.27 billion in 2025 and is projected to grow from USD 25.70 billion in 2026 to USD 54.88 billion by 2033, at a CAGR of 11.4% from 2026 to 2033. North America psoriasis drugs market held the largest share of 38.3% of the global market in 2025. The psoriasis drugs market is witnessing strong growth driven by advances in immunomodulators, increasing adoption of biologic therapies, and favorable reimbursement support across developed healthcare markets.
Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases
Continuous research and development activities are contributing to treatment innovation, particularly for moderate to severe psoriasis cases, thereby supporting demand for targeted therapies. A major market trend is the increasing competition from biosimilars, which is reshaping the competitive landscape for established biologics and improving treatment accessibility. Growing acceptance of biosimilars among healthcare providers and payers is helping reduce herapy costs and expand patient access, especially in cost-sensitive markets. In addition, the market continues to shift toward advanced interleukin inhibitors and targeted oral therapies due to their improved efficacy, longer treatment durability, and favorable clinical outcomes compared to conventional systemic treatments.The market is also experiencing a strong shift toward precision-based psoriasis management, supported by the increasing preference for targeted biologics and next-generation oral therapies. Interleukin inhibitors targeting IL-17 and IL-23 pathways continue to gain significant commercial traction due to their high skin clearance rates, rapid onset of action, and sustained therapeutic response. Pharmaceutical companies are actively focusing on lifecycle management strategies, label expansions, and development of improved formulations to strengthen product positioning in the competitive immunology segment. In addition, increasing physician awareness regarding long-term disease management and comorbidity reduction is contributing to higher adoption of advanced psoriasis therapeutics.
Rising prevalence of chronic inflammatory skin disorders and increasing demand for long-term disease management therapies continue to support the growth of the psoriasis drugs market. The market is benefiting from higher adoption of advanced biologics and targeted therapies that offer improved efficacy, better symptom control, and enhanced patient outcomes compared to conventional treatments. In addition, increasing healthcare expenditure, expanding access to specialty dermatology care, and growing awareness regarding early diagnosis and treatment are further contributing to market expansion. Continuous product innovation, broader biosimilar availability, and ongoing regulatory support for novel psoriasis therapies are expected to sustain competitive development and create favorable growth opportunities for the market during the forecast period.
Global Psoriasis Drugs Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global psoriasis drugs market report based on class, treatment, route of administration, distribution channel, and region:
- Class Outlook (Revenue, USD Billion, 2021 - 2033)
- Tumor Necrosis Factor Inhibitors
- Interleukin Inhibitors
- Vitamin D Analogues
- Corticosteroids
- Others
- Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
- Topicals
- Systemic
- Biologics
- Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
- Oral
- Parenteral
- Topical
- Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Other Pharmacies
- Regional Outlook (Revenue, USD Billion, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Segment Definitions
- 1.2.1. Class
- 1.2.2. Treatment
- 1.2.3. Route of Administration
- 1.2.4. Distribution Channel
- 1.3. Estimates and Forecast Timeline
- 1.4. Research Methodology
- 1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
- 1.6. Information Analysis
- 1.6.1. Data Analysis Models
- 1.7. Market Formulation & Data Visualization
- 1.8. Model Details
- 1.8.1. Commodity Flow Analysis
- 1.9. List of Secondary Sources
- 1.10. Objectives
Chapter 2. Executive Summary
- 2.1. Market Snapshot
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Psoriasis Drugs Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
- 3.3.1.1. Supplier Power
- 3.3.1.2. Buyer Power
- 3.3.1.3. Substitution Threat
- 3.3.1.4. Threat of New Entrants
- 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
Chapter 4. Psoriasis Drugs Market: Class Business Analysis
- 4.1. Class Market Share, 2025 & 2033
- 4.2. Class Segment Dashboard
- 4.3. Market Size & Forecasts and Trend Analysis, by Class, 2021 to 2033 (USD Billion)
- 4.4. Tumor Necrosis Factor Inhibitors
- 4.4.1. Tumor Necrosis Factor Inhibitors Market, 2021 - 2033 (USD Billion)
- 4.5. Interleukin Inhibitors
- 4.5.1. Interleukin Inhibitors Market, 2021 - 2033 (USD Billion)
- 4.6. Vitamin D Analogues
- 4.6.1. Vitamin D Analogues Market, 2021 - 2033 (USD Billion)
- 4.7. Corticosteroids
- 4.7.1. Corticosteroids Market, 2021 - 2033 (USD Billion)
- 4.8. Others
- 4.8.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 5. Psoriasis Drugs Market: Treatment Business Analysis
- 5.1. Treatment Market Share, 2025 & 2033
- 5.2. Treatment Segment Dashboard
- 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
- 5.4. Topicals
- 5.4.1. Topicals Market, 2021 - 2033 (USD Billion)
- 5.5. Systemic
- 5.5.1. Systemic Market, 2021 - 2033 (USD Billion)
- 5.6. Biologics
- 5.6.1. Biologics Market, 2021 - 2033 (USD Billion)
Chapter 6. Psoriasis Drugs Market: Route of Administration Business Analysis
- 6.1. Route of Administration Market Share, 2025 & 2033
- 6.2. Route of Administration Segment Dashboard
- 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Billion)
- 6.4. Oral
- 6.4.1. Oral Market, 2021 - 2033 (USD Billion)
- 6.5. Parenteral
- 6.5.1. Parenteral Market, 2021 - 2033 (USD Billion)
- 6.6. Topical
- 6.6.1. Topical Market, 2021 - 2033 (USD Billion)
Chapter 7. Psoriasis Drugs Market: Distribution Channel Business Analysis
- 7.1. Distribution Channel Market Share, 2025 & 2033
- 7.2. Distribution Channel Segment Dashboard
- 7.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Billion)
- 7.4. Hospital Pharmacies
- 7.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.5. Retail Pharmacies
- 7.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
- 7.6. Other Pharmacies
- 7.6.1. Other Pharmacies Market, 2021 - 2033 (USD Billion)
Chapter 8. Psoriasis Drugs Market: Regional Estimates & Trend Analysis
- 8.1. Regional Market Share Analysis, 2025 & 2033
- 8.2. Regional Market Dashboard
- 8.3. Market Size & Forecasts Trend Analysis, 2021 to 2033
- 8.4. North America
- 8.4.1. North America Psoriasis Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
- 8.4.2. U.S.
- 8.4.2.1. Key Country Dynamics
- 8.4.2.2. Target Disease Prevalence
- 8.4.2.3. Regulatory Framework
- 8.4.2.4. Reimbursement Framework
- 8.4.2.5. U.S. Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.3. Canada
- 8.4.3.1. Key Country Dynamics
- 8.4.3.2. Target Disease Prevalence
- 8.4.3.3. Regulatory Framework
- 8.4.3.4. Reimbursement Framework
- 8.4.3.5. Canada Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.4.4. Mexico
- 8.4.4.1. Key Country Dynamics
- 8.4.4.2. Target Disease Prevalence
- 8.4.4.3. Regulatory Framework
- 8.4.4.4. Reimbursement Framework
- 8.4.4.5. Mexico Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5. Europe
- 8.5.1. Europe Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.2. UK
- 8.5.2.1. Key Country Dynamics
- 8.5.2.2. Target Disease Prevalence
- 8.5.2.3. Regulatory Framework
- 8.5.2.4. Reimbursement Framework
- 8.5.2.5. UK Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.3. Germany
- 8.5.3.1. Key Country Dynamics
- 8.5.3.2. Target Disease Prevalence
- 8.5.3.3. Regulatory Framework
- 8.5.3.4. Reimbursement Framework
- 8.5.3.5. Germany Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.4. France
- 8.5.4.1. Key Country Dynamics
- 8.5.4.2. Target Disease Prevalence
- 8.5.4.3. Regulatory Framework
- 8.5.4.4. Reimbursement Framework
- 8.5.4.5. France Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.5. Italy
- 8.5.5.1. Key Country Dynamics
- 8.5.5.2. Target Disease Prevalence
- 8.5.5.3. Regulatory Framework
- 8.5.5.4. Reimbursement Framework
- 8.5.5.5. Italy Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.6. Spain
- 8.5.6.1. Key Country Dynamics
- 8.5.6.2. Target Disease Prevalence
- 8.5.6.3. Regulatory Framework
- 8.5.6.4. Reimbursement Framework
- 8.5.6.5. Spain Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.7. Denmark
- 8.5.7.1. Key Country Dynamics
- 8.5.7.2. Target Disease Prevalence
- 8.5.7.3. Regulatory Framework
- 8.5.7.4. Reimbursement Framework
- 8.5.7.5. Denmark Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.8. Sweden
- 8.5.8.1. Key Country Dynamics
- 8.5.8.2. Target Disease Prevalence
- 8.5.8.3. Regulatory Framework
- 8.5.8.4. Reimbursement Framework
- 8.5.8.5. Sweden Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.5.9. Norway
- 8.5.9.1. Key Country Dynamics
- 8.5.9.2. Target Disease Prevalence
- 8.5.9.3. Regulatory Framework
- 8.5.9.4. Reimbursement Framework
- 8.5.9.5. Norway Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6. Asia Pacific
- 8.6.1. Asia Pacific Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.2. Japan
- 8.6.2.1. Key Country Dynamics
- 8.6.2.2. Target Disease Prevalence
- 8.6.2.3. Regulatory Framework
- 8.6.2.4. Reimbursement Framework
- 8.6.2.5. Japan Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.3. China
- 8.6.3.1. Key Country Dynamics
- 8.6.3.2. Target Disease Prevalence
- 8.6.3.3. Regulatory Framework
- 8.6.3.4. Reimbursement Framework
- 8.6.3.5. China Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.4. India
- 8.6.4.1. Key Country Dynamics
- 8.6.4.2. Target Disease Prevalence
- 8.6.4.3. Regulatory Framework
- 8.6.4.4. Reimbursement Framework
- 8.6.4.5. India Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.5. Australia
- 8.6.5.1. Key Country Dynamics
- 8.6.5.2. Target Disease Prevalence
- 8.6.5.3. Regulatory Framework
- 8.6.5.4. Reimbursement Framework
- 8.6.5.5. Australia Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.6. South Korea
- 8.6.6.1. Key Country Dynamics
- 8.6.6.2. Target Disease Prevalence
- 8.6.6.3. Regulatory Framework
- 8.6.6.4. Reimbursement Framework
- 8.6.6.5. South Korea Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.6.7. Thailand
- 8.6.7.1. Key Country Dynamics
- 8.6.7.2. Target Disease Prevalence
- 8.6.7.3. Regulatory Framework
- 8.6.7.4. Reimbursement Framework
- 8.6.7.5. Thailand Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7. Latin America
- 8.7.1. Latin America Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.2. Brazil
- 8.7.2.1. Key Country Dynamics
- 8.7.2.2. Target Disease Prevalence
- 8.7.2.3. Regulatory Framework
- 8.7.2.4. Reimbursement Framework
- 8.7.2.5. Brazil Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.7.3. Argentina
- 8.7.3.1. Key Country Dynamics
- 8.7.3.2. Target Disease Prevalence
- 8.7.3.3. Regulatory Framework
- 8.7.3.4. Reimbursement Framework
- 8.7.3.5. Argentina Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8. Middle East and Africa
- 8.8.1. Middle East and Africa Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.2. South Africa
- 8.8.2.1. Key Country Dynamics
- 8.8.2.2. Target Disease Prevalence
- 8.8.2.3. Regulatory Framework
- 8.8.2.4. Reimbursement Framework
- 8.8.2.5. South Africa Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.3. Saudi Arabia
- 8.8.3.1. Key Country Dynamics
- 8.8.3.2. Target Disease Prevalence
- 8.8.3.3. Regulatory Framework
- 8.8.3.4. Reimbursement Framework
- 8.8.3.5. Saudi Arabia Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.4. UAE
- 8.8.4.1. Key Country Dynamics
- 8.8.4.2. Target Disease Prevalence
- 8.8.4.3. Regulatory Framework
- 8.8.4.4. Reimbursement Framework
- 8.8.4.5. UAE Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
- 8.8.5. Kuwait
- 8.8.5.1. Key Country Dynamics
- 8.8.5.2. Target Disease Prevalence
- 8.8.5.3. Regulatory Framework
- 8.8.5.4. Reimbursement Framework
- 8.8.5.5. Kuwait Psoriasis Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
Chapter 9. Competitive Landscape
- 9.1. Participant Overview
- 9.2. Company Market Position Analysis
- 9.3. Company Categorization
- 9.4. Strategy Mapping
- 9.5. Company Profiles/Listing
- 9.5.1. AbbVie Inc.
- 9.5.1.1. Overview
- 9.5.1.2. Financial Performance
- 9.5.1.3. Product Benchmarking
- 9.5.1.4. Strategic Initiatives
- 9.5.2. Amgen Inc.
- 9.5.2.1. Overview
- 9.5.2.2. Financial Performance
- 9.5.2.3. Product Benchmarking
- 9.5.2.4. Strategic Initiatives
- 9.5.3. Johnson & Johnson Services, Inc.
- 9.5.3.1. Overview
- 9.5.3.2. Financial Performance
- 9.5.3.3. Product Benchmarking
- 9.5.3.4. Strategic Initiatives
- 9.5.4. Novartis AG
- 9.5.4.1. Overview
- 9.5.4.2. Financial Performance
- 9.5.4.3. Product Benchmarking
- 9.5.4.4. Strategic Initiatives
- 9.5.5. Eli Lilly And Company
- 9.5.5.1. Overview
- 9.5.5.2. Financial Performance
- 9.5.5.3. Product Benchmarking
- 9.5.5.4. Strategic Initiatives
- 9.5.6. Celgene Corporation
- 9.5.6.1. Overview
- 9.5.6.2. Financial Performance
- 9.5.6.3. Product Benchmarking
- 9.5.6.4. Strategic Initiatives
- 9.5.7. UCB S.A.
- 9.5.7.1. Overview
- 9.5.7.2. Financial Performance
- 9.5.7.3. Product Benchmarking
- 9.5.7.4. Strategic Initiatives
- 9.5.8. Merck
- 9.5.8.1. Overview
- 9.5.8.2. Financial Performance
- 9.5.8.3. Product Benchmarking
- 9.5.8.4. Strategic Initiatives
- 9.5.9. Boehringer Ingelheim International GmbH
- 9.5.9.1. Overview
- 9.5.9.2. Financial Performance
- 9.5.9.3. Product Benchmarking
- 9.5.9.4. Strategic Initiatives
- 9.5.1. AbbVie Inc.
